Lantheus Appointed Syntermed as the First Distributor of Pylarify AI in the US
Shots:
- Pylarify is the first and only FDA approved AI platform developed to assist standardized quantification of PSMA PET/CT scans
- The AI platform employs a deep learning algorithm that has been trained and validated across 3,000+ images allowing HCPs and researchers to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer
- Pylarify has shown improved consistency, accuracy, and efficiency in the PSMA PET/CT quantitative assessment. The imaging system is revolutionizing the visualization of prostate cancer metastases and thus the staging of the disease. The medical device software is now commercially available in the US
Ref: PR Web | Image: Lantheus
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
